-
Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
-
Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
Most of us dread the chief complaint of weakness. This nonspecific symptom engenders a differential that ranges from malingering to fatal, from psychiatric to cancer. The finding of demonstrable muscle weakness helps, but then leads to a confusing set of relatively rare diagnoses.
-
-
A fascinating, philosophical exchange among some of the nation's leading health care epidemiologists recently came down to the value of zero.
-
As the field of infection prevention undergoes sweeping changes, the Society for Healthcare Epidemiology of America (SHEA) must reassess its role and redefine its mission, an epidemiologist said recently in Orlando at the group's annual meeting.
-
In the silence after the speakers had concluded the opening session recently in Orlando of the annual meeting of the Society for Healthcare Epidemiology of America (SHEA) as those with questions were moving to the microphones moderator Patrick J. Brennan, MD, acknowledged what many were thinking by noting that there was an "800-pound gorilla in the room."
-
State hospital associations throughout the nation should be in receipt of a May 6, 2008, letter from U.S. Rep. Henry Waxman, chairman of the Committee on Oversight and Government Reform, asking what they are doing to prevent health care-associated infections (HAIs).
-
Hospital infection prevention efforts aimed at methicillin-resistant Staphylococcus aureus (MRSA) appear to having some effect in preventing nosocomial transmission.
